LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, ...

All proceeds from the book sale will be donated to Sepsis Alliance and Donate Life America LEXINGTON, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid ...

LEXINGTON, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the ...

T2 Biosystems has received FDA clearance to add the capability to detect another bacterial species, Acinetobacter baumannii, to its panel. T2 Biosystems is set to report its fourth-quarter financial ...

LEXINGTON, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today affirmed plans to ...

You're in the hospital and your vital signs are shutting down. Doctors can't figure out why but they give you a series of blood tests -- fearing you might have a deadly infection. If they can discover ...

T2 Biosystems ( (TTOO)) has provided an update. T2 Biosystems, Inc. held its annual meeting of stockholders, where key corporate governance matters were addressed, including the approval of an ...

Shares of diagnostic test and device developer T2 Biosystems (TTOO 133.33%) jumped as much as 16.1% today after a volatile week. The good news is that the company recently announced that the U.S. Food ...

LEXINGTON, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that CEO John Sperzel released a ...